Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 154,542 shares, a growth of 116.7% from the December 15th total of 71,326 shares. Based on an average daily volume of 86,690 shares, the short-interest ratio is currently 1.8 days. Currently, 2.3% of the shares of the stock are short sold. Currently, 2.3% of the shares of the stock are short sold. Based on an average daily volume of 86,690 shares, the short-interest ratio is currently 1.8 days.

Calidi Biotherapeutics Stock Performance

Shares of CLDI stock traded down $0.08 during trading hours on Thursday, hitting $1.04. The stock had a trading volume of 102,518 shares, compared to its average volume of 74,289. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.11. Calidi Biotherapeutics has a one year low of $1.03 and a one year high of $19.20. The stock’s 50-day moving average price is $1.34 and its two-hundred day moving average price is $2.70.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($2.21) earnings per share for the quarter. As a group, research analysts anticipate that Calidi Biotherapeutics will post -4.48 EPS for the current year.

Hedge Funds Weigh In On Calidi Biotherapeutics

A hedge fund recently bought a new stake in Calidi Biotherapeutics stock. Warberg Asset Management LLC acquired a new position in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 18,705 shares of the company’s stock, valued at approximately $28,000. Warberg Asset Management LLC owned approximately 0.55% of Calidi Biotherapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.